financetom
Business
financetom
/
Business
/
Swiss finance minister says tariff deal with US depends on Trump
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Swiss finance minister says tariff deal with US depends on Trump
Nov 6, 2025 5:44 AM

ZURICH, Nov 6 (Reuters) - Swiss efforts to secure a more

favourable trade relationship with the U.S. are ongoing, Finance

Minister Karin Keller-Sutter said on Thursday, after Swiss

corporate bosses met with U.S. President Donald Trump earlier

this week.

Switzerland was left reeling after Trump imposed tariffs of 39%

on Swiss imports in August, among the highest duties levied in

his global trade reset.

Keller-Sutter, who has come under fire for her handling of

the dispute, said she had fulfilled her duties as Switzerland's

president when she spoke to Trump before the tariffs

announcement.

"He did not agree with the negotiated agreement. Period,"

she told newspaper Blick in an article published on Thursday.

"We have to live with that. The talks are continuing."

She remained tight-lipped on the negotiations, or whether an

agreement could be reached this year.

"Ultimately, it is up to the U.S. president to decide

whether or not to agree to a deal," Keller-Sutter said.

Swiss companies have also been working to persuade Trump to

reduce the tariffs, with a delegation of business leaders

meeting Trump in the White House on Tuesday.

The group, which included executives from shipping company

MSC, watchmaker Rolex, investment firm Partners Group,

commodities trader Mercuria, Cartier-owner Richemont and

precious metals firm MKS, had organised to draw attention to the

consequences of U.S. tariffs on their companies, Switzerland's

economy ministry said.

The government welcomed the initiative.

"Diplomatic and political exchanges are continuing with a

view to achieving a rapid reduction in additional tariffs," the

ministry added.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Japan's union group Rengo announces biggest wage hikes on record
Japan's union group Rengo announces biggest wage hikes on record
Mar 22, 2024
TOKYO (Reuters) -Japanese firms have agreed to raise pay by 5.25% this year, the biggest rise under comparable data since 2013, the country's largest union group Rengo confirmed on Friday. The results of the closely-watched wage negotiations are announced in several stages, in which the blue-chip firms are first to wrap up their talks in mid-March. The second announcement on...
Once a beacon of stability, Vietnam to name third president in a year
Once a beacon of stability, Vietnam to name third president in a year
Mar 22, 2024
HANOI, March 22 (Reuters) - Communist-ruled Vietnam is seeking its third president in little more than a year after the resignation of Vo Van Thuong, who was only elected last year after the sudden dismissal of his predecessor. With accumulated foreign direct investment higher than its gross domestic product, Vietnam's stability is crucial to multinationals with large operations in the...
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Mar 22, 2024
(Reuters) - Popular investor Cathie Wood's ARK Invest bought nearly 10,000 shares of Reddit ( RDDT ) in the social media platform's strong market debut on Thursday, an email from the asset manager showed. A total of 9,982 shares of the loss-making company was added to ARK Next Generation Internet ETF ( ARKW ) and ARK Fintech Innovation ETF (...
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Mar 22, 2024
05:04 AM EDT, 03/22/2024 (MT Newswires) -- Hutchmed ( HCM ) said late Thursday it has started the registration stage for a phase 2/3 clinical trial of investigational drug sovleplenib for adult patients with warm antibody autoimmune hemolytic anemia in China. The move follows positive data from the proof-of-concept phase 2 stage of the trial and a consultation with the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved